MedPath

Assessment of efficacy and safety of immunotherapy for unresectable locally advanced pancreatic cancer.

Phase 1
Conditions
pancreatic ductal carcinoma
Registration Number
JPRN-UMIN000000769
Lead Sponsor
agoya University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
15
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with immunologic abnormalities

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
OS
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath